艾伯维旗下新药获重要药品监管机构认定 艾伯维公司于5月24日宣布，其候选药物upadacitinib获得国家药品监督管理局药品审评中心(CDE)突破性治疗药物 ...

Upadacitinib demonstrated significant clinical and endoscopic remission in Crohn's disease patients, including those with prior advanced therapy exposure, without new safety signals. The study ...

Upadacitinib shows sustained efficacy in UC, with over half maintaining clinical remission through 144 weeks in a phase 3 LTE study. Real-world data from the IBD-DACH study confirmed upadacitinib ...

A total of 209 patients received upadacitinib at a dose of 15 mg, 107 received upadacitinib at a dose of 7.5 mg, and 112 received placebo; 70% of the patients had new-onset giant-cell arteritis ...

colon The U-ACCOMPLISH induction study evaluated the efficacy and safety of upadacitinib in 515 adults with moderate to severe ulcerative colitis. A phase 3 induction study evaluating upadacitinib ...

For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December ...

NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib), 15 mg, once daily ...

The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for giant cell arteritis (GCA) in adults. This is the first oral JAK inhibitor indicated for ...